Clinical trial
A Double-Blind, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA
NCT00144521 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA
- Lead sponsor
- Chugai Pharmaceutical
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 29, 2004
- Completion date
- April 30, 2006
- Enrollment
- 127 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
rheumatoid arthritis